Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
19.05. | From insight to impact: How eCOAs strengthen trial data quality | ||
19.05. | Bridging the data gaps that impact retail and specialty-lite success | ||
16.05. | BioMarin to buy rare disease drugmaker Inozyme for $270M | ||
16.05. | Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff | ||
16.05. | Novo CEO to depart as obesity drugmaker's challenges rise | ||
15.05. | A bespoke CRISPR therapy suggests a blueprint for treating 'N-of-1' diseases | ||
15.05. | FDA delays approval decision for Biohaven rare disease drug | ||
15.05. | Sanofi to pour more than $20B into US drug research and manufacturing | ||
15.05. | AbbVie stakes $335M on a startup's RNAi drugs | ||
15.05. | Stopping a 'moral obscenity': Senate Judiciary Committee expresses support for PBM reform | ||
14.05. | Novo to work with Septerna in hunt for oral obesity drugs | ||
14.05. | Bluebird extends deal deadline; Affimed files for insolvency | ||
14.05. | GSK to buy liver disease drug for $1.2B | ||
13.05. | Women's health faces growing headwinds, despite jump in venture investment | ||
13.05. | 5 questions on Trump's plan to lower US drug prices | ||
13.05. | Galapagos backtracks on planned split | ||
13.05. | iTeos, GSK to shelve TIGIT drug after study setback | ||
13.05. | Andrew Witty steps down as UnitedHealth CEO | ||
12.05. | FDA follows EMA in limiting use of Valneva shot | ||
12.05. | Trump revives 'most favored nation' plan in effort to cut US drug prices | ||
12.05. | Abeona sells speedy drug review voucher for $155M | ||
12.05. | Innovating a healthier tomorrow: Entering a new era of medicine | ||
12.05. | [Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care | ||
09.05. | Eli Lilly extends Purdue alliance; EMA investigates Valneva shot | ||
08.05. | 4 more biotechs cut staff amid market tumult |